Skip to main content
OCGN
NASDAQ Life Sciences

Ocugen 推进基因治疗管道，目标于2027年获得OCU400批准

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$1.82
Mkt Cap
$609.872M
52W Low
$0.515
52W High
$1.96
Market data snapshot near publication time

summarizeSummary

Ocugen 提供了全面业务更新，详细介绍了其在治疗失明疾病的基因治疗管道方面取得的重大进展。主要亮点包括完成OCU400的3期招募，预计在2027年第一季度公布顶级数据，并可能在2027年获得FDA批准。该公司还报告称，OCU410ST的2/3期试验即将完成招募，预计在2026年第三季度公布中期数据。此外，Ocugen 宣布了OCU400的区域许可协议，标志着其商业化战略的开始。虽然伴随的2025年第四季度和全年财务结果基本如预期且已先前报告，但这些管道进展和战略发展为公司提供了关键的前瞻性催化剂。交易者将密切关注这些项目的即将公布的数据和监管里程碑。

在该公告发布时，OCGN的交易价格为$1.82，交易所为NASDAQ，所属行业为Life Sciences，市值约为$6.1亿。 52周交易区间为$0.52至$1.96。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed OCGN - Latest Insights

OCGN
Apr 28, 2026, 7:01 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Ocugen's Annual Meeting Proxy Omits Reverse Stock Split Proposal
Sentiment: Negative
View Wiseek Article
OCGN
Apr 20, 2026, 5:18 PM EDT
Filing Type: PRER14A
Importance Score:
8
Ocugen Amends Reverse Stock Split Proposal, Lowers Minimum Ratio to 1:2 Amidst Going Concern
Sentiment: Negative
View Wiseek Article
OCGN
Apr 17, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Ocugen Seeks Shareholder Approval for Reverse Stock Split Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article
OCGN
Mar 27, 2026, 6:03 AM EDT
Source: Wiseek News
Importance Score:
8
Ocugen Completes Phase 3 Enrollment for Two Gene Therapies, Targets Three BLA Submissions by 2028
Sentiment: Positive
View Wiseek Article
OCGN
Mar 26, 2026, 7:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Ocugen Details Positive OCU410 Phase 2 Data & Comprehensive Gene Therapy Pipeline in Investor Presentation
Sentiment: Positive
View Wiseek Article
OCGN
Mar 24, 2026, 7:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
OCU410 Gene Therapy Reduces Geographic Atrophy Lesion Growth by 31% in Positive Phase 2 Data; Ocugen to Advance to Phase 3
Sentiment: Positive
View Wiseek Article
OCGN
Mar 23, 2026, 7:02 AM EDT
Source: GlobeNewswire
Importance Score:
7
Ocugen to Present Phase 2 OCU410 Gene Therapy Data for Geographic Atrophy on March 24
Sentiment: Neutral
View Wiseek Article
OCGN
Mar 20, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Ocugen Secures $15M from Warrant Exercise, Extends Cash Runway Amidst Going Concern
Sentiment: Positive
View Wiseek Article
OCGN
Mar 04, 2026, 3:03 PM EST
Source: Wiseek News
Importance Score:
9
Ocugen Reports Positive OCU410 Phase 2 Data, Secures Cash Runway Beyond 2026
Sentiment: Positive
View Wiseek Article
OCGN
Mar 04, 2026, 11:38 AM EST
Filing Type: 10-K
Importance Score:
9
Ocugen's 10-K Reveals Going Concern, Limited Cash Runway, and Ongoing Legal Battle Over Share Count
Sentiment: Negative
View Wiseek Article